SMTIHIGH SIGNALRISK10-K

SMTI experienced a catastrophic decline in stockholders' equity of 85% alongside substantially higher debt levels, indicating severe financial distress.

The near-complete erosion of shareholder equity combined with rising debt levels suggests the company may be facing a liquidity crisis or significant operational challenges that have fundamentally impaired its financial position. The removal of forward-looking business strategy language and core business descriptions from the filing further indicates potential strategic uncertainty or restructuring activity.

Comparing 2026-03-24 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

While revenue grew meaningfully by 33% and gross profit expanded modestly, these operational improvements were completely overshadowed by a devastating 85% collapse in stockholders' equity from $39.4M to just $5.9M. Total debt increased substantially to $46.0M, and total assets declined 17%, painting a picture of a company experiencing severe financial deterioration despite top-line growth. The dramatic equity destruction suggests either massive losses, significant write-downs, or other extraordinary charges that have fundamentally compromised the company's financial foundation.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-84.9%
$39.4M→$5.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Debt
Balance Sheet
+49.8%
$30.7M→$46.0M

Debt increased 49.8% — substantial leverage increase; assess whether deployed for growth or covering losses.

Inventory
Balance Sheet
+43.4%
$2.8M→$3.9M

Inventory surged 43.4% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Liabilities
Balance Sheet
+36.3%
$49.2M→$67.0M

Liabilities grew 36.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
+32.5%
$11.8M→$15.6M

Strong top-line growth of 32.5% — accelerating demand or successful expansion into new markets.

Current Liabilities
Balance Sheet
+21.8%
$15.3M→$18.6M

Current liabilities rose 21.8% — increased short-term obligations, watch current ratio.

Gross Profit
P&L
+21.7%
$78.5M→$95.6M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Total Assets
Balance Sheet
-17.2%
$88.1M→$72.9M

Total assets contracted 17.2% — asset sales, write-downs, or balance sheet optimization underway.

R&D Expense
P&L
-11.1%
$5.7M→$5.1M

R&D spending cut 11.1% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-03-25
ADDED
As of March 20, 2026, 9,167,040 shares of the registrant s common stock, $ 0.001 par value per share, were issued and outstanding.
MARKET FOR REGISTRANT S COMMON EQUITY, RELATED SHAREHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES 39 ITEM 6.
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 39 ITEM 7A.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 53 ITEM 9A.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 54 ITEM 13.
FORM 10-K SUMMARY 58 Sanara, Sanara MedTech, our logo and our other trademarks or service marks appearing in this report are the property of Sanara MedTech Inc.
Forward-looking statements generally relate to future events or our future financial or operating performance, including topics such as new products under development.
BUSINESS Overview We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market.
Our products are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for healthcare systems.
We strive to be one of the most innovative and comprehensive providers of effective surgical solutions and are continually seeking to expand our offerings for patients requiring surgical treatments in the United States.
REMOVED
As of March 18, 2025, 8,901,903 shares of the Issuer s common stock, $ 0.001 par value per share, were issued and outstanding.
Forward-looking statements generally relate to future events or our future financial or operating performance, including topics such as our value-based wound and skincare services and Tissue Health Plus platforms.
BUSINESS Overview We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets.
Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for patients regardless of where they receive care.
Through our two operating segments, Sanara Surgical and Tissue Health Plus ( THP ), we strive to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and are continually seeking to expand our offerings for patients requiring treatments across the entire continuum of care in the United States.
Reportable Segments Historically, we managed our business on the basis of one operating and reportable segment.
During the second quarter of 2024, we changed our reportable segments to reflect a change in the manner in which the business is managed.
Based on the growing importance of the value-based wound care program to our future outlook and how our chief operating decision maker, our Chief Executive Officer, reviews operating results and makes decisions about resource allocation, we now have two reportable segments: Sanara Surgical and THP.
Sanara Surgical Our Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments.
Sanara Surgical s soft tissue repair products include, among other products, our lead product, CellerateRX Surgical Activated Collagen ( CellerateRX Surgical ), a hydrolyzed collagen that supports a local environment for surgical sites to aid in the natural wound healing process, and BIASURGE Advanced Surgical Solution ( BIASURGE ), a sterile no-rinse, advanced surgical solution used for wound irrigation.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →